EXCLUSIVE LICENSE AND OPTION AGREEMENTExclusive License and Option Agreement • January 25th, 2019 • Mereo Biopharma Group PLC • Pharmaceutical preparations • New York
This EXCLUSIVE LICENSE AND OPTION AGREEMENT (the “Agreement”) is made and entered into effective as of 28 October 2017 (the “Effective Date”) by and between ASTRAZENECA AB, a company incorporated in Sweden under no. 556011-7482 with its registered office at SE-151 85 Sodertalje, Sweden (“AstraZeneca”), and MEREO BIOPHARMA 4 LIMITED, a company incorporated in England and Wales under no. 11029583 with its registered office at 4th Floor, One, Cavendish Place, London, W1G 0QF (“Mereo”). AstraZeneca and Mereo are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
SECOND AMENDED AND RESTATED EXCLUSIVE LICENSE AND OPTION AGREEMENT BY AND BETWEEN BAYLOR COLLEGE OF MEDICINE AND CELL MEDICA, INC. (d/b/a KUUR THERAPEUTICS) Original Effective Date: APRIL 29, 2016 First Restatement Effective Date: FEBRUARY 28, 2020...Exclusive License and Option Agreement • March 16th, 2022 • Athenex, Inc. • Pharmaceutical preparations • New York
This Second Amended and Restated Exclusive License and Option Agreement (the “Second Restated Agreement” or “Agreement” herein), effective as of October 12, 2021 (the “Second Restatement Effective Date”), is by and between Baylor College of Medicine (“Baylor”), a Texas nonprofit corporation having its principal place of business at One Baylor Plaza, Houston, Texas 77030, and Cell Medica Inc., doing business as Kuur Therapeutics, a Texas corporation with its principal place of business at 6200 Savoy Dr., #1200, Houston TX 77036 (“Kuur”, collectively the “Parties”, individually, a “Party.”) As of the Second Restatement Effective Date, this Second Restated Agreement amends and restates that certain Amended and Restated Exclusive License and Option Agreement (the “First Restated Agreement”), entered into on February 28, 2020, (the “First Restatement Effective Date”) by Baylor and Kuur Therapeutics Ltd. (formerly known as Cell Medica Ltd.), and as assigned by Kuur Therapeutics Ltd. to Cell
EXCLUSIVE LICENSE and OPTION AGREEMENTExclusive License and Option Agreement • February 8th, 2011 • Cyplasin Biomedical Ltd. • Pharmaceutical preparations • Nevada
This Exclusive License Agreement (the “Agreement”) is entered into as of February 7, 2009 (the “Effective Date”), by and between Bioxen Ltd including its affiliates, legal successors and subsidiaries with its principal offices registered as Nautilus House, La Cour des Casernes, St.Helier.Jersey, JE1 3NH, Channel Islands (“Bioxen”) and Cyplasin Biomedical Ltd., a (Nevada corporation), with its principal offices located at Unit 131 Advanced Technology Center, 9650-20th ave., Edmonton, Alberta Canada T6N1G1 including its affiliates, legal successors and subsidiaries, (“Cyplasin”); and collectively referred to as the “Parties”; and
EXCLUSIVE LICENSE AND OPTION AGREEMENTExclusive License and Option Agreement • November 9th, 2011 • Cleveland Biolabs Inc • Services-commercial physical & biological research • New York
This Exclusive License and Option Agreement (“Agreement”) is made effective as of September 23, 2011 (“Effective Date”) by and between Children’s Cancer Institute Australia for Medical Research, , a not for profit medical institute formed under the laws of Australia with registration number ACN 072 279 559 (“CCIA”), and Panacela Labs, Inc., a Delaware corporation (“Panacela”). The parties hereto are additionally referred to individually as a “Party”, and collectively, the “Parties”.
AMENDED AND RESTATED EXCLUSIVE LICENSE AND OPTION AGREEMENT BY AND BETWEEN BAYLOR COLLEGE OF MEDICINE ANDExclusive License and Option Agreement • August 5th, 2021 • Athenex, Inc. • Pharmaceutical preparations • New York
This Amended and Restated Exclusive License and Option Agreement (the “Restated Agreement”), effective as of February 28, 2020 (the “Restatement Effective Date”), is by and between Baylor College of Medicine (“Baylor”), a Texas nonprofit corporation having its principal place of business at One Baylor Plaza, Houston, Texas 77030, and Kuur Therapeutics Limited (formerly known as Cell Medica, Ltd.) (Reg. No. 05620555), a private limited company organized under the laws of England and Wales and having a principal place of business at 1 Canal Side Studios, 8-14 St Pancras Way, London, NW1 0QG, United Kingdom (“Cell Medica” or “Kuur”). As of the Restatement Effective Date, this Restated Agreement amends and restates the License and Option Agreement dated April 29, 2016, as amended by that certain First Amendment dated May 26, 2017, that certain Second Amendment dated December 5, 2017, that certain Third Amendment dated May 17, 2018, that certain Fourth Amendment dated December 19, 2018, and
EXCLUSIVE LICENSE AND OPTION AGREEMENT by and between FibroGen, Inc. and HiFiBiO (HK) Limited (d.b.a. HiFiBiO Therapeutics) Dated as of June 16, 2021Exclusive License and Option Agreement • August 9th, 2021 • Fibrogen Inc • Pharmaceutical preparations • Delaware
THIS EXCLUSIVE LICENSE AND OPTION AGREEMENT (this “Agreement”) is entered into as of June 16, 2021 (the “Effective Date”) by and among HiFiBiO (HK) Limited (d.b.a. HiFiBiO Therapeutics), a limited company organized and existing under the laws of Hong Kong, with a registered address at Room 303, Third Floor, St. George’s Building, 2 Ice House Street, Central, Hong Kong (“HFB”), and FibroGen, Inc., a Delaware corporation having its principal place of business at 409 Illinois St., San Francisco, CA 94158 (“FibroGen”). HFB and FibroGen are referred to herein individually as a “Party” and collectively as the “Parties.”
EXCLUSIVE LICENSE AND OPTION AGREEMENTExclusive License and Option Agreement • November 9th, 2011 • Cleveland Biolabs Inc • Services-commercial physical & biological research • New York
This Exclusive License and Option Agreement (“Agreement”) is made effective as of September 23, 2011 (“Effective Date”) by and between Health Research, Inc., Roswell Park Institute Division, a domestic not-for-profit corporation (“HRI”), Roswell Park Cancer Institute Corporation, a New York corporation (“RPCI”) (HRI and RPCI are, collectively, “RPCI”), and Panacela Labs, Inc., a Delaware corporation (“Panacela”). The parties hereto are additionally referred to individually as a “Party”, and collectively, the “Parties”.
